M.

Erick Edwards, Ann Harper – 21 September 2004 – Key Points 1Based on OPTN data, the ability of the model for end‐stage liver disease (MELD) to predict short‐term pretransplant and posttransplant outcomes was assessed.2Concordance with pretransplant mortality was excellent.3Concordance with pretransplant mortality was better for candidates listed for a primary transplant.4Of the MELD components, there were no statistically significant differences in the effects on pretransplant mortality between candidates listed for a primary or a repeat transplant.5Concordance with posttranplant outcomes w

Russell H. Wiesner – 21 September 2004 – Key Points 1Historical perspective of donor allocation to patients with fulminant hepatic failure (FHF).2Predicting prognosis in patients with FHF using the London and Clichy criteria.3Model for end‐stage liver disease (MELD) is a predictor of mortality in patients with FHF.4Outcomes of adults listed as Status 1 in the United States.5Outcomes of pediatric candidates listed as Status 1 in the United States.6Proposed redefinition for Status 1 in adult and pediatric candidates. (Liver Transpl 2004;10:S17–S22.)

Julie K. Heimbach, Michael G. Haddock, Steven R. Alberts, Scott L. Nyberg, Michael B. Ishitani, Charles B. Rosen, Gregory J.

Sue V. McDiarmid, Robert M. Merion, Dawn M. Dykstra, Ann M.

James R. Burton, Amnon Sonnenberg, Hugo R. Rosen – 21 September 2004 – Key Points 1Retransplantation (re‐LT) for hepatitis C virus (HCV) recurrence is controversial. Although re‐LT accounts for 10% of all liver transplants (LTs), the number of patients requiring re‐LT is expected to grow as primary LT recipients survive long enough to develop graft failure from recurrent disease.2Utility, as applied to the medical ethics of transplantation, refers to allocating organs to those individuals who will make the best use of them.

John Fung, Bijan Eghtesad, Kusum Patel‐Tom, Michael DeVera, Holly Chapman, Margaret Ragni – 21 September 2004 – Key Points 1Liver transplantation for human immunodeficiency virus (HIV)‐positive patients with end‐stage liver disease in the era of highly active retroviral therapy has proven to be an effective treatment.

Robert M.

Michael R.

Simon Horslen – 21 September 2004 – Key Points 1Patients listed for combined liver and intestine transplantation have the highest waitlist mortality of any transplant candidates.2Liver‐intestine candidates have higher mortality rates than other patients listed for liver transplantation at all model for end‐stage liver disease (MELD) and pediatric end‐stage liver disease (PELD) scores, sepsis rather than liver failure being the major cause of death in this group.3Increasing PELD scores appear to correlate with increasing waitlist mortality in patients awaiting combined liver and intestinal t